Brady James Parker sold $58K of ARDX

Brady James Parker (Chief Human Resources Officer) sold 15,136 shares of ARDELYX, INC. (ARDX) at $3.86 across 2 trades on 2026-08-21.

Original reporting
SEC EDGAR · Brady James Parker
Published Aug 25, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect ARDX's stock price or investor sentiment.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or compensation changes not disclosed.

Relevance 3/10Novelty 4/10Timing: filing date 2026-08-25

Background

Form 4 filing discloses insider trades to the SEC; required for transparency.

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

Chief Human Resources Officer Brady James Parker sold 15,136 shares for $58,378, reducing his stake to 245,930 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to market cap and typical insider trading volumes.

Market effects

None; HR executive sale does not affect sector dynamics.

None; company is US‑listed with limited regional relevance.

None; isolated insider transaction.

Counterpoint

Even small insider sales can signal concerns, but no corroborating evidence here.

Key entities

  • Brady James Parker

    Chief Human Resources Officer of ARDELYX, Inc.

  • ARDELYX, Inc.

    Biopharmaceutical company listed under ticker ARDX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.